Correlation Between Sarepta Therapeutics and Axsome Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Sarepta Therapeutics and Axsome Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sarepta Therapeutics and Axsome Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sarepta Therapeutics and Axsome Therapeutics, you can compare the effects of market volatilities on Sarepta Therapeutics and Axsome Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sarepta Therapeutics with a short position of Axsome Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sarepta Therapeutics and Axsome Therapeutics.

Diversification Opportunities for Sarepta Therapeutics and Axsome Therapeutics

-0.75
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Sarepta and Axsome is -0.75. Overlapping area represents the amount of risk that can be diversified away by holding Sarepta Therapeutics and Axsome Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Axsome Therapeutics and Sarepta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sarepta Therapeutics are associated (or correlated) with Axsome Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Axsome Therapeutics has no effect on the direction of Sarepta Therapeutics i.e., Sarepta Therapeutics and Axsome Therapeutics go up and down completely randomly.

Pair Corralation between Sarepta Therapeutics and Axsome Therapeutics

Given the investment horizon of 90 days Sarepta Therapeutics is expected to under-perform the Axsome Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Sarepta Therapeutics is 2.23 times less risky than Axsome Therapeutics. The stock trades about -0.15 of its potential returns per unit of risk. The Axsome Therapeutics is currently generating about 0.12 of returns per unit of risk over similar time horizon. If you would invest  9,908  in Axsome Therapeutics on December 1, 2024 and sell it today you would earn a total of  2,846  from holding Axsome Therapeutics or generate 28.72% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Sarepta Therapeutics  vs.  Axsome Therapeutics

 Performance 
       Timeline  
Sarepta Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Sarepta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Axsome Therapeutics 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Axsome Therapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Axsome Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Sarepta Therapeutics and Axsome Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Sarepta Therapeutics and Axsome Therapeutics

The main advantage of trading using opposite Sarepta Therapeutics and Axsome Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sarepta Therapeutics position performs unexpectedly, Axsome Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Axsome Therapeutics will offset losses from the drop in Axsome Therapeutics' long position.
The idea behind Sarepta Therapeutics and Axsome Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Other Complementary Tools

Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.